Commercial Services and Supplies
Company Overview of Medical Research Council
Medical Research Council is based in London, United Kingdom.
One Kemble Street
London, WC2B 4AN
Founded in 1913
Key Executives for Medical Research Council
Deputy Chief Executive, Chief of Strategy and Director of National Institute for Medical Research
Director of External Affairs
Compensation as of Fiscal Year 2016.
Medical Research Council Key Developments
Medical Research Council Develops a New Approach to Speed Up MRI scans
Jul 28 15
Medical Research Council scientists have developed a new approach to speed up MRI scans for those who cannot hold their breath. Testing the new approach on MRI scans of the liver in patients with type 2 diabetes, the researchers were able to cut the amount of time they're required to hold their breath from 18 seconds to just four. MRI is a type of scan that can provide detailed images of organs and soft tissue inside the body and is widely used to diagnose and monitor disease and health. While the technique can provide incredibly detailed images, patients need to lie completely still and in some cases hold their breath for several seconds which for many can be difficult. The new MRI technique exploits the fact that MRI images can be mathematically compressed in a similar way to digital photographs stored in JPEG files. This compressibility means that much less data is needed to form a detailed view of the liver. Normally, reducing the scan time to this degree would produce a blurred image, but the new approach was able to form an image with the same clarity and content as the much longer scan.
Medical Research Council and GlaxoSmithkline to Collaborate on Unique Open Innovation Research Initiative
Jul 15 15
Medical Research Council (MRC) and GlaxoSmithKline (GSK) and five leading UK universities collaborate to crack difficult disease areas. MRC and GSK are to collaborate on a unique open innovation research initiative aiming to improve scientists' understanding of inflammatory diseases that present a serious burden to patients. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL, with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases. It is hoped that combining the disease biology expertise of these academic scientists with GSK's drug development expertise and resources will ultimately lead to breakthroughs in understanding that could accelerate the development of innovative treatments for patients. The initiative aims to support up to ten experimental medicine projects over the five year period. The academic research teams that are awarded funding by the MRC will work alongside their industry colleagues at both GSK and university facilities, with a view to building a legacy of expertise in translational and experimental human research across academia and industry. It is anticipated that the network will grow beyond the first five academic partners.
Medical Research Council Appoints Sharmila Nebhrajani OBE as Director of External Affairs, Effective from February 23, 2015
Feb 12 15
The Medical Research Council announced the appointment of Sharmila Nebhrajani OBE as Director of External Affairs, from February 23, 2015. Shar is currently Chair of the Human Tissue Authority. Her responsibilities for the MRC include leading on the MRCs engagement with key stakeholders, in particular Parliamentarians and Government, on the importance and impact of the MRCs work and achievements; she will also contribute to the forthcoming Spending Review. Shar will be working closely with other medical research funders and academies, and with industry partners.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries